|
|
|
|
Merck's interest in non-PPI products to be acquired by AstraZeneca
Pharmaceutical company Merck & Co Inc (NYSE:MRK) said on Monday that Anglo-Swedish pharmaceutical company AstraZeneca plc (LSE:AZN) (NYSE:AZN) (OMX:AZN) will exercise its option to acquire Merck's interest in certain partnership products.AstraZeneca...
|
|
|
AstraZeneca to buy Merck's interest in non-proton pump inhibitor products
Merck & Co, Inc has been advised by AstraZeneca PLC that it will exercise the option to obtain Merck's interest in AstraZeneca's non-proton pump inhibitor (non-PPI) products this year.Those products are Atacand, Lexxel, Plendil and Entocort plus...
|
|
|
AstraZeneca Exercises Option to Acquire Merck's Interest in Partnership Products
Merck & Co., Inc.(MSD) announced yesterday that it has been advised by AstraZeneca PLC that it will exercise the option to obtain Merck's interest in AstraZeneca's non-proton pump inhibitor (non-PPI) products this year. Those products are Atacand,...
|
|
|
AstraZeneca buys out Mercks rights to a number of drugs
AstraZeneca is paying Merck & Co $647 million in order to get back the rights to a number of products covered by the firms US joint venture.The Anglo-Swedish drugmaker is exercising an option which will see Merck relinquish the rights to Entocort ...
|
|
|
Goldman Sachs Group bats enquiry calls
Written by Will Peters Morning finance news in brief, 02 March 2010: Goldman Sachs Group, Greek financial crisis, AstraZaneca and Vivendi.Goldman Sachs Group (NYSE:GS) has seen their board reject demands from shareholders that an enquiry is conducted into...
|
|
|
Goldman Sachs Group firm on compensation enquiry
: Goldman Sachs Group, Greek financial crisis, AstraZaneca and Vivendi.Goldman Sachs Group (NYSE:GS) has seen their board reject demands from shareholders that an enquiry is conducted into recent compensation awards. The rejection, and details of the...
|
|
|
Merck's interest in non-PPI products to be acquired by AstraZeneca
( ) Mar 02, 2010 (M2 EQUITYBITES via COMTEX) -- Pharmaceutical company Merck & Co Inc (NYSE:MRK) said on Monday that Anglo-Swedish pharmaceutical company AstraZeneca plc (LSE:AZN) (NYSE:AZN) (OMX:AZN) will exercise its option to acquire Merck's interest...
|
|
|
AstraZeneca to buy Merck's interest in partnership for $647mn
British pharma giant Astra Zeneca said it was buying Merck's interest in their partnership for $647 million.Both companies are part of AstraZeneca's non-proton pump inhibitor (non-PPI) products partnership. Those products are Atacand, Lexxel, Plendil...
|
|
|
AstraZeneca to acquire Merck's interest in non-proton pump inhibitor products
Merck & Co has reported that it has been advised by AstraZeneca that it will exercise the option to obtain Merck's interest in AstraZeneca's non-proton pump inhibitor, or non-PPI products in 2010.The non-PPI products are Atacand, Lexxel, Plendil...
|
|
|
Merck's interest in non-PPI products to be acquired by AstraZeneca
Pharmaceutical company Merck & Co Inc (NYSE:MRK) said on Monday that Anglo-Swedish pharmaceutical company AstraZeneca plc (LSE:AZN) (NYSE:AZN) (OMX:AZN) will exercise its option to acquire Merck's interest in certain partnership products.AstraZeneca...
|
|
|
AstraZeneca Exercises Option To Acquire Merck's Interest In Partnership Products
Merck & Co., Inc.announced recently that it has been advised by AstraZeneca PLC that it will exercise the option to obtain Merck's interest in AstraZeneca's non-proton pump inhibitor (non-PPI) products this year. Those products are Atacand , Lexxel ...
|
|
|
Astra unties part of US Merck deal for $647 million
LONDON: AstraZeneca said on Monday it was exercising an option with Merck & Co to take back full rights to certain drugs marketed in the United States and would pay the U.S.group $647 million in April. The payout, which had been anticipated by...
|
|
|
AZ Exercises Merck non-PPI Buyout
AstraZeneca will exercise its option to buy out Merck's interest in AZ's non-proton pump inhibitor (non-PPI) products this year for $647 million.The products are Atacand, Lexxel, Plendil and Entocort, as well as several products in development. AZ...
|
|
|
AstraZeneca buys Merck drugs
AstraZeneca Plc will "excercize the option to buy Merck's interest in AstraZeneca's non-proton pump inhibitor products" (Atacand, Lexxel and Plendil, which fight high blood pressure, and Entocort, for Krohn's disease) "plus certain products in clinical...
|
|
|
AstraZeneca buys Merck drugs
AstraZeneca Plc will "excercize the option to buy Merck's interest in AstraZeneca's non-proton pump inhibitor products" (Atacand, Lexxel and Plendil, which fight high blood pressure, and Entocort, for Krohn's disease) "plus certain products in clinical...
|
|
|
'New' Merck has 40 drugs in mid-, late-stage tests
Drugmaker Merck & Co.says it now has about 40 experimental drugs in mid- or late-stage development as a result of its recent deal to buy New Jersey neighbor Schering-Plough Corp. The combined company, which has operations in the Philadelphia region,...
|
|
|
Stocks Push Higher, Led by Technology
Stocks advanced Monday, buoyed by some merger activity and expectations that a Greek bailout is coming soon.Techs were out in front, with Intel leading the Dow and the Nasdaq up more than 1 percent, after a report showed chip sales were up a whopping 47...
|
|
|
Post-Schering: Merck touts survivors, AZ buys cast-offs
AstraZeneca Plc will "excercize the option to buy Merck's interest in AstraZeneca's non-proton pump inhibitor products" (Atacand, Lexxel, Plendil, which fight high blood pressure, and Entocort, a treatment for Krohn's disease of the digestive tract) "plus...
|
|
|
AstraZeneca to pay Merck $647 million for rights to drugs
Merck, which is based in Hunterdon County, is selling its interest in certain drugs to AstraZeneca.Whitehouse Station-based Merck said AstraZeneca will excercise an option to buy the former's interest in non-proton pump inhibitor products such as Atacand,...
|
|
|
AstraZeneca Exercises Option to Acquire Merck's Interest in Partnership Products
- Merck & Co., Inc.announced today that it has been advised by AstraZeneca PLC that it will exercise the option to obtain Merck's interest in AstraZeneca's non-proton pump inhibitor (non-PPI) products this year. Those products are Atacand, Lexxel, ...
|
|
|
'New' Merck has 40 drugs in mid-, late-stage tests
Drugmaker Merck & Co.says it now has about 40 experimental drugs in mid- or late-stage development as a result of its recent deal to buy New Jersey neighbor Schering-Plough Corp. The combined company, which has operations in the Philadelphia region,...
|
|
|
AZ to pay $647M for Merck rights
AstraZeneca has exercised its option to buy out Merck's interest in some of its products, planning to pay its U.S.rival $647 million for its share of blood pressure drugs Atacand, Lexxel and Plendil, and the Crohn's disease treatment Entocort. Some...
|
|
|
New Merck has 40 drugs in mid-, late-stage tests
Drugmaker Merck & Co.says it now has about 40 experimental drugs in mid- or late-stage development as a result of its recent deal to buy New Jersey neighbor Schering-Plough Corp. The combined company, which has operations in the Philadelphia region,...
|
|
|
AstraZeneca to pay Merck $647 million for rights to drugs
Merck, which is based in Hunterdon County, is selling its interest in certain drugs to AstraZeneca.Whitehouse Station-based Merck said AstraZeneca will excercise an option to buy the former's interest in non-proton pump inhibitor products such as Atacand,...
|
|
|
AstraZeneca Uses Option To Buy Out Some Merck Product Interest
LONDON -(Dow Jones)- U.K.pharmaceutical firm AstraZeneca PLC (AZN.LN) Monday said it will exercise an option with Merck & Co. (MRK) to retake full rights to certain drugs sold in the U.S. and pay the drug maker $647 million in April. Products...
|
